Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Biomarkers. Found 14 abstracts

Jung S, Allen N, Arslan AA, Baglietto L, Brinton LA, Egleston BL, Falk R, Fortner RT, Helzlsouer KJ, Idahl A, Kaaks R, Lundin E, Merritt M, Onland-Moret C, Rinaldi S, Sanchez MJ, Sieri S, Schock H, Shu XO, Sluss PM, Staats PN, Travis RC, Tjonneland A, Trichopoulou A, Tworoger S, Visvanathan K, Krogh V, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF. Demographic, lifestyle, and other factors in relation to antimullerian hormone levels in mostly late premenopausal women. Fertility and sterility. 2017 Apr;107(4):1012-1022 e2.   PMCID: PMC5426228
Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH. The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. Contemporary clinical trials. 2017 Jul 21;61:63-72.
Garrigan C, Han J, Tolomeo P, Johnson KJ, Master SR, Lautenbach E, Nachamkin I. Evaluation of a research use only luminex based assay for measurement of procalcitonin in serum samples. American journal of translational research. 2016 Jan;8(10):4362-9.   PMCID: PMC5095329
Haggerty AF, Huepenbecker S, Sarwer DB, Spitzer J, Raggio G, Chu CS, Ko E, Allison KC. The use of novel technology-based weight loss interventions for obese women with endometrial hyperplasia and cancer. Gynecol Oncol. 2016 Feb;140(2):239-44.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2016 Dec;68(6):959-67.
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Thunnissen E, Blaauwgeers HJ, de Cuba EM, Yick CY, Flieder DB. Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung. Arch Pathol Lab Med. 2016 Mar;140(3):212-20.
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015 May;33(13):1482-90.   PMCID: PMC4404425
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Hasan N, Kumar R, Kavuru M. Lung Cancer Screening Beyond Low-Dose Computed Tomography: The Role of Novel Biomarkers. Lung. 2014 Oct;192(5):639-48.
Merali S, Barrero CA, Bowler RP, Chen DE, Criner G, Braverman A, Litwin S, Yeung A, Kelsen SG. Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. COPD. 2014 Apr;11(2):177-89.   PMCID: 4497366
Gaudet MM, Falk RT, Gierach GL, Lacey JV, Graubard BI, Dorgan JF, Brinton LA. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?. Cancer Epidemiology. 2010 Oct;34(5):580-6.   PMCID: PMCID: PMC2949443 [Available on 2011/10/1]
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. Journal of Proteome Research. 2009 Jan;8(1):113-7.   PMCID: PMC 2655764
Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Research. 2003 Jan;63(24):8695-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Biomarkers

Biomarkers Middle Aged Male therapeutic use Female Aged metabolism Prospective Studies diagnosis pathology drug therapy Adult blood Antineoplastic Agents Neoadjuvant chemotherapy adverse effects Prognosis Cisplatin sensitivity 80 and over Aged Treatment Outcome Cisplatin resistance Rb1 Fancc Urothelial carcinoma Lymphedema Atm Obesity Breast cancer Bladder cancer Cyclopentanes Drug Administration Schedule Severity of Illness Index Premenopause Multiple Myeloma Proteomics Standard Operating Enzyme-Linked Immunosorbent Assay genetics Bronchioles analogs & derivatives Sex Hormone-Binding Globulin promoter hypermethylation gene kidney cancer diagnosis Prednisone analysis Ubiquitins Life Style Blood Proteins Respiratory Mucosa Urine (promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients for early diagnosis and prognosis) Adenocarcinoma Lung Sensitivity and Specificity Epidemiology Diagnosis (cancer Monoclonal Antibodies procalcitonin Ovarian Reserve Urinary Bladder Neoplasms Neoadjuvant Therapy blood supply Oral Contraceptives-Hormonal Relapse Lung cancer screening Europe sepsis resistin levels unclassified) APC protein Role: BSU (Biological study-DGN (Diagnostic use)-BIOL (Biological study)-USES (Uses) (promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients for early diagnosis and prognosis) Human Smooth Muscle European Continental Ancestry Group Pyrimidines Case-Control Studies Neoplasm Drug Resistance unclassified) Gene Role: BSU (Biological study-PRP (Properties)-BIOL (Biological study) (TIMP-3 Antimullerian hormone serum adiponectin Kaplan-Meier Estimate United States Retreatment Bronchiolitis Obliterans Rituximab Lung Diseases Procedures unclassified) Gene Role: BSU (Biological study-PRP (Properties)-BIOL (Biological study) (CDKN2A Weight loss intervention metabolic Artifacts Antineoplastic Combined Chemotherapy Protocols Genetic Markers Low-dose computed tomography unclassified) DNA Role: BSU (Biological study-BIOL (Biological study) (hypermethylation Lymphoma Specimen Handling unclassified) Gene Role: BSU (Biological study-DGN (Diagnostic use)-PRP (Properties)-BIOL (Biological study)-USES (Uses) (p14ARF Lung Neoplasms Neoplasm Seeding Sample handling Consensus classification Liquid Chromatography Genome-Wide Association Study Maximum Tolerated Dose Diagnostic Errors epidemiology unclassified) Proteins Role: BSU (Biological study-DGN (Diagnostic use)-BIOL (Biological study)-USES (Uses) (p14ARF Age Factors Biopsy Molecular Targeted Therapy Risk Factors luminex reproductive factors pharmacology Tumor markers Disease Progression Vitamin D Deficiency Differential Diagnosis surgery Multivariate Analysis unclassified) Proteins Role: BSU (Biological study-DGN (Diagnostic use)-BIOL (Biological study)-USES (Uses) (gene RASSF1A (Ras assocn domain family 1 isoform A) Cisplatin Forced Expiratory Volume estrogen unclassified) Gene Role: BSU (Biological study-DGN (Diagnostic use)-PRP (Properties)-BIOL (Biological study)-USES (Uses) (RASSF1A unclassified) Promoter Role: BSU (Biological study-BIOL (Biological study) (promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients for early diagnosis and prognosis) unclassified) Gene Role: BSU (Biological study-PRP (Properties)-BIOL (Biological study) (VHL DNA Repair syndrome Local Neoplasm Recurrence Muscle Contraction fat Asia mortality adipose-tissue Chronic Obstructive Pulmonary Disease Proportional Hazards Models Adipokines research use only (RUO) assays promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients for early diagnosis and prognosis) demographic Cross-Sectional Studies Testosterone Congeners Anti-Mullerian Hormone Young Adult Neoplasm Invasiveness Doxorubicin Vincristine release Disease-Free Survival Vitamin D Plasma collection
Last updated on Wednesday, September 06, 2017